Premium
Rationale for the Development of Recombinant Human CC10 as a Therapeutic for Inflammatory and Fibrotic Disease
Author(s) -
PILON APRILE L.
Publication year - 2000
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/j.1749-6632.2000.tb05536.x
Subject(s) - proteases , recombinant dna , transgene , disease , in vivo , computational biology , biology , receptor , medicine , bioinformatics , immunology , cancer research , microbiology and biotechnology , pathology , genetics , biochemistry , gene , enzyme
A bstract : CC10/uteroglobin is a remarkable protein whose physiological roles have only recently been explored in vivo . Both transgenic mice that have been rendered deficient and humans that have been characterized as deficient in this protein exhibit tendencies toward inflammatory, fibrotic, and oncologic disease, demonstrating the potential of the protein as a therapeutic agent. The protein itself is an excellent candidate for clinical development because of its inherent physical properties. It is relatively small, resistant to proteases, stable to extremes of heat and pH, and can be produced by recombinant methods. The physiological roles of this multifunctional protein continue to be uncovered as research progresses in vitro , in animals, and eventually in humans. The pathways through which CC10 mediates its effects, its receptors, and other family members will be a rich source of exciting research, as well as potential diagnostic and therapeutic agents. This paper is an introductory, noncomprehensive review of some of the scientific and medical rationale in support of CC10‐based therapies in selected clinical applications.